Trial Profile
Efficacy and Safety of Oral Kanglaite (KLTc) in Men With Prostate Cancer: Randomized, Dose-Ranging Study of the Effects of KLTc on Prostate Specific Antigen (PSA) Doubling Time Among Men With Rising PSA Levels After Definitive Local Therapy.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Kanglaite (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- Sponsors KangLaiTe USA
- 15 Jan 2014 According to ClinicalTrials.gov record; study status changed from active, no longer recruiting to discontinued.
- 06 Aug 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
- 25 Jan 2012 Planned End Date (1 Dec 2013) added as reported by ClinicalTrials.gov.